Literature DB >> 12694184

Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins.

Eveliina Ihanus1, Liisa Uotila, Anne Toivanen, Michael Stefanidakis, Pascal Bailly, Jean-Pierre Cartron, Carl G Gahmberg.   

Abstract

Intercellular adhesion molecule-4 (ICAM-4, LW blood group antigen), a member of the immunoglobulin superfamily expressed on red cells, has been reported to bind to CD11a/CD18 and CD11b/CD18 leukocyte integrins. The location of the ICAM-4 binding sites on CD11a/CD18 and CD11b/CD18 are not known. CD11/CD18 integrin I domains have been found to act as major binding sites for physiological ligands and a negatively charged glutamic acid in ICAMs is considered important for binding. ICAM-4 lacks such a residue, which is replaced by an arginine. However, we demonstrate here that ICAM-4 in red cells and transfected fibroblasts interacts specifically with the I domains of CD11a/CD18 and CD11b/CD18 integrins. The binding was inhibited by anti-I domain and anti-ICAM-4 antibodies and it was dependent on divalent cations. Interestingly, ICAM-4 negative red cells were still able to bind to the CD11b/CD18 I domain but the binding of these cells to the CD11a/CD18 I domain was clearly reduced. Using a solid phase assay, we were able to show that isolated I domains directly and specifically bind to purified recombinant ICAM-4 in a cation dependent manner. Competition experiments indicated that the binding sites in ICAM-4 for the CD11a and CD11b I domains are different. However, the ICAM-4 binding region in both I domains seems to overlap with the regions recognized by the ICAM-1 and ICAM-2. Thus we have established that the I domains contain an ICAM-4 binding region in CD11a/CD18 and CD11b/CD18 leukocyte integrins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694184     DOI: 10.1046/j.1432-1033.2003.03528.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  12 in total

Review 1.  Fibrinogen, red blood cells, and factor XIII in venous thrombosis.

Authors:  B L Walton; J R Byrnes; A S Wolberg
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 2.  Leukocyte arrest: Biomechanics and molecular mechanisms of β2 integrin activation.

Authors:  Zhichao Fan; Klaus Ley
Journal:  Biorheology       Date:  2015       Impact factor: 1.875

Review 3.  Leukocyte integrins and their ligand interactions.

Authors:  Young-Min Hyun; Craig T Lefort; Minsoo Kim
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

4.  Potato crop as a source of emetic Bacillus cereus and cereulide-induced mammalian cell toxicity.

Authors:  Douwe Hoornstra; Maria A Andersson; Vera V Teplova; Raimo Mikkola; Liisa M Uotila; Leif C Andersson; Merja Roivainen; Carl G Gahmberg; Mirja S Salkinoja-Salonen
Journal:  Appl Environ Microbiol       Date:  2013-03-22       Impact factor: 4.792

5.  Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice.

Authors:  Cristina R Carter; James P Whitcomb; Jessica A Campbell; Rami M Mukbel; Mary Ann McDowell
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

6.  Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity.

Authors:  Jiaxi Wu; Huaizhu Wu; Jinping An; Christie M Ballantyne; Jason G Cyster
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-11       Impact factor: 11.205

7.  Microparticle surface modifications targeting dendritic cells for non-activating applications.

Authors:  Jamal S Lewis; Toral D Zaveri; Charles P Crooks; Benjamin G Keselowsky
Journal:  Biomaterials       Date:  2012-07-12       Impact factor: 12.479

8.  The CD11a partner in Sus scrofa lymphocyte function-associated antigen-1 (LFA-1): mRNA cloning, structure analysis and comparison with mammalian homologues.

Authors:  Philippe G A C Vanden Bergh; Thomas Fett; Laurent L M Zecchinon; Anne V T Thomas; Daniel J M Desmecht
Journal:  BMC Vet Res       Date:  2005-10-10       Impact factor: 2.741

9.  FRET based quantification and screening technology platform for the interactions of leukocyte function-associated antigen-1 (LFA-1) with intercellular adhesion molecule-1 (ICAM-1).

Authors:  Sandeep Chakraborty; David Núñez; Shih-Yang Hu; María Pilar Domingo; Julian Pardo; Artashes Karmenyan; Arthur Chiou
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

10.  Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.

Authors:  Miok Kim; Seon-Jin Lee; Sangsu Shin; Kang-Seo Park; Sang Yoon Park; Chang Hoon Lee
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.